Kodiak Sciences Q2 net loss widens on higher R&D costs

Kodiak Sciences

13/08/2026 21:08

Overview
Retina-focused biotech's Q2 net loss widened yr/yr as R&D expenses increased
Company ended Q2 with $125.9 mln in cash, expects funding to last into 2027
Company advanced Phase 3 trials for Zenkuda, KSI-501 and KSI-101; topline data expected in coming quarters

Outlook
Kodiak expects DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in September 2026
Company anticipates PEAK Phase 3 Pivotal Analysis 1 topline data for KSI-101 in December 2026
Kodiak says current cash and equivalents expected to support operations into 2027

Result Drivers
HIGHER R&D SPENDING - Co said increased Q2 R&D expenses were mainly due to greater clinical and manufacturing activities for Phase 3 programs

Company press release: ID:nPnc7K0c9a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.05
 
Q2 Net Loss
 
$65.64 mln
 
Q2 Loss Per Basic Share
 
$1.05
 
Q2 Operating Expenses
 
$66.84 mln
 
Q2 Operating Income
 
-$66.84 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kodiak Sciences Inc. is $61.50, about 41.7% above its August 12 closing price of $43.41

Reuters Recommended Reads
Aug 13 - Belite Bio Q2 net loss widens on higher expenses
Aug 11 - Eye care company Alcon raises margin outlook, shares jump
Aug 11 - Kalaris Therapeutics Q2 net loss narrows on lower administrative costs 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)